Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
James A Radosevich, Michael Babich LabyRx Immunologic Therapeutics (USA) Limited, Sacramento, California, USACorrespondence: James A Radosevich 1009 Johnson Ct, Belvidere, IL 61008 Tel +1 530 330 5888Email jrados@labyrx.comAbstract: A paradigm shift is currently underway on the relationship between...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-11-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/labyrinthin-the-tumor-marker-recognized-by-mca-44-3a6-a-case-for-pan-t-peer-reviewed-article-OTT |